Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Trinity Biotech (TRIB)
:TRIB
Holding TRIB?
Track your performance easily
Earnings Data
Report Date
Apr 02, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.37Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 23, 2018
|% Change Since: -43.92%
|Next Earnings Date:Jul 19, 2018
Earnings Call Sentiment|Neutral
The earnings call reflected a company in transition, with significant improvements in revenue growth and cost reduction measures. However, challenges remain, particularly in the hemoglobin segment and overall net loss, indicating a mixed outlook.Company Guidance
During Trinity Biotech's Q3 2024 earnings call, the company reiterated its guidance for 2024, projecting TrinScreen HIV sales revenue of approximately $10 million and annualized run rate revenues of around $75 million by Q2 2025. The company reported a 3% year-on-year revenue growth, reaching $15.2 million for Q3 2024, primarily driven by a 60% increase in point-of-care revenues due to TrinScreen sales. Operating loss improved by 51% to $2.2 million before restructuring and impairment charges. The company aims to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025 through comprehensive transformation initiatives, including cost reductions and operational efficiencies.Revenue Growth in Q3 2024
The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.
TrinScreen HIV Sales Projection
Trinity Biotech reiterated its guidance for TrinScreen sales of approximately $10 million for the full year 2024, reflecting strong market demand.
Reduction in Operating Loss
The operating loss before restructuring and impairment charges decreased to $2.2 million from $4.5 million in Q3 2023, marking a 51% improvement.
NASDAQ Listing Compliance Achieved
The company successfully addressed NASDAQ listing deficiencies, removing an important overhang on its stock.
Cost Reduction Initiatives
SG&A expenses decreased by $1.2 million to $6.5 million in Q3 2024, showcasing effective cost reduction measures.
---
TRIB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TRIB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 15, 2024 | $1.48 | $1.37 | -7.43% |
| Aug 14, 2024 | $2.46 | $2.53 | +2.85% |
| May 23, 2024 | $1.56 | $1.63 | +4.49% |
| Apr 04, 2024 | $2.03 | $2.00 | -1.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Trinity Biotech (TRIB) report earnings?
Trinity Biotech (TRIB) is schdueled to report earning on Apr 02, 2025, TBA Not Confirmed.
What is Trinity Biotech (TRIB) earnings time?
Trinity Biotech (TRIB) earnings time is at Apr 02, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TRIB EPS forecast?
TRIB EPS forecast for the fiscal quarter 2024 (Q4) is -0.3.
---